Clinical Trial

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

Name: First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors — clinical trial record (NCT07362888)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Protocol Amendment History 1 change

critical Recruitment opened 2026-04-16

Trial Details

NCT Number	NCT07362888
Lead Sponsor	Adcendo ApS
Conditions	Solid Tumors (Phase 1)
Enrollment	180 participants
Start Date	2026-03-17
Primary Completion	2026-12-31 (estimated)
Study Completion	2029-03-14 (estimated)
Updated on ClinicalTrials.gov	2026-07-24